MHE Staff

The Philadelphia-based insurer has selected four winners.

Adam Fein, founder of Drug Channels, said the acquisition will allow the company to upgrade its technology, grow the company and provide live and in-person events.

We caught up recently with William Shrank, M.D., a longtime member of the Managed Healthcare Executive editorial advisory board. Shrank has held several executive positions with health insurers, most recently Humana. He is now a venture partner with Andreessen Horowitz, a venture capital firm in Menlo Park, California.

Seven New Members from Diverse Health Care Professions, Organizations and Industries Join Board.

We asked 16 industry professionals what their predictions are for health care in 2024.

Brent Dover is the CEO of Carta Healthcare. He predicts that AI use will reach new heights.

Matt Hollingsworth is the Chief Innovation Officer and Co-Founder of Carta Healthcare. He said there will be a growing need for technology in 2024.

Greg Baker is the CEO of AffirmedRx. He predicts that "transparent PBMs will gain traction" in 2024.

François de Brantes, M.S., MBA is a senior partner at HVC Incentives Advisory Group LLC and a member of Managed Healthcare Executive editorial advisory board. He predicts "price distortions will be revealed" in 2024.

Fran Gregory, Pharm.D., MBA is the Vice President of Emerging Therapies at Cardinal Health. She thinks 2024 will be an exciting year for cell and gene therapy.

Melynda Barnes, M.D. is the Chief Medical Officer at Ro. She believes "more people will gain access to GLP-1 inhibitors" in 2024.

Michael Meucci is the CEO of Arcadia. He thinks that EHRs will get an AI makeover.

Maulik P. Purohit, M.D., M.P.H., is the Chief Health Information Officer at the Lehigh Valley Health Network. He believes that "AI will enhance the patient experience" in 2024.

Joerg Schwarz, M.S., is the Senior Director of Healthcare Interoperability at Infor. He believes providers will harness the power of generative AI in 2024.

Brianna Zink, M.S.N, is the Senior Director of Health Care Product Strategy at Infor. She says staff ratios will become a burden in 2024.

This year's top multimedia content includes a video interview with Jennifer Roggenbuck, MS, LGC, of Ohio State University, who addresses the patient journey of ALS.

Laura Kline, MBA, CPCU is the Senior Vice President of Business Development at The Doctors Company. She predicts "APCs will be critical to access care."

Casberg is Vice President of Clinical Pharmacy at IPD Analytics LLC and a member of the Managed Healthcare Executive editorial advisory board. He predicts that "payers will tighten" in 2024.

This year's top HIV articles include one sharing data from a group of researchers from University of Pittsburgh who looked to see if T cell activation is sufficient to drive SIV disease progression.

Kelsay is the President and CEO of the Business Group on Health. She predicts that in 2024, employers will "sound the drug price alarm."

Robert E. White Jr. is the President of The Doctors Company. He believes "social inflation will affect malpractice insurers."

This year's top oncology news included a study that suggested low-fat meals could affect blood concentration levels, and high blood concentration has been associated with a better response to the drug, Alecensa.

Weight-loss medications were very much in the news this year, and the pages and website of Managed Healthcare Executive were no exception. Articles on off-label use of the GLP-1s such as Ozempic (semaglutide) and the FDA approval of Zepbound (tirzepatide) garnered the most page views.

Articles about Humira biosimilars, over-the-counter hearing aids and specialty drugs were among those about healthcare and drug costs that had the most pageviews on the MHE website in 2023.

News about state bans on accumulators, Pfizer’s announcements about vaccines and cardiovascular deaths increasing because of climate change were the most viewed news items on the Managed Healthcare Executive website this year.

Articles about upcoming approvals and Humira biosimilars were among those that garnered the most interest.

IDose TR will be available in first quarter of 2024 with a wholesale acquisition cost of $13,950 per dose/implant.

Rising healthcare costs impact their own organization’s competitiveness, said those who responded to the Pulse of the Purchaser survey by the National Alliance of Healthcare Purchaser Coalitions.

Mike Tuffin is set to become AHIP's President and CEO from January 8, 2024, succeeding Julie Simon Miller.